Neurimmune inks US-$760 deal with AstraZeneca
Neurimmune has entered into a collaboration and license agreement with AstraZeneca subsidiary Alexion Pharmaceuticals to commercialise its antibody NI006.
Santhera finds Chinese marketing partner for vamorolone
Swiss Santhera Pharmaceuticals has entered into a $124m licence deal with Chinese Sperogenix Therapeuticis to market its DMD drug vamorolone.
DNA Script bags US$200m financing
Moderna’s US-French partner DNA Script has raised additional $35m as a second tranche of a Series C financing to advance its Enzymatic DNA Synthesis platform, Syntax.
Sound Bioventures Fund I AB closes at 110m
Novo Holdings, together with Saminvest, Vækstfonden, the European Investment Fund and its three co-founders have put 110m in the first fund of Sound Bioventures AB.
Omicron variant more harmless than Delta
The new year begins with good news.
Season Greetings
Merry Christmas and a Happy New Year!
Novo Holdings invests 86m in 21st.BIO
Novo Holdings is set to invest 86m in 21st.BIO A/S a new Danish bioindustrial scale-up company to boost the production of proteins.
Novartis AG snags Gyroscope for US$1.5bn
Ocular gene therapy specialist Gyroscope Therapeutics Holdings plc is to be acquired by Novartis AG for up to $1.5bn.
NorthSea Therapeutics completes US$80m Series C financing
Dutch metabolic disease specialist NorthSea Therapeutics NV has baged US$80m in a Series C fundraising co-led by Ysios Capital and Forbion Growth.
Depixus raises 30.6m in Series A financing
French-British magnetic trap specialist Depixus has raised 30,6m to develop a commercial instrument based on the companys MAGNA technology.